ClinicalTrials.gg
Active, not recruitingNCT06569108Updated Sep 17, 2025

Efficacy and Safety of KN057 Prophylaxis in Patients With Haemophilia A or B Without Inhibitors

A Phase 3 interventional study of KN057 in Hemophilia A Without Inhibitor and Hemophilia B Without Inhibitor, sponsored by Suzhou Alphamab Co., Ltd.. Active, not recruiting at 1 site in China. Open to male participants aged 12 Years to 70 Years. Per ClinicalTrials.gov, last updated 2025-09-17.

Sponsored by Suzhou Alphamab Co., Ltd. · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
125
Allocation
Randomized
Ages
12 Years to 70 Years
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 93 studies in Hemophilia A with a site in China — 28 open to participants now, 39 under way, 19 of them phase 3. Hemophilia A · China.

Enrollment
10th of 80
125 · median 54
Started
2024
with 9 others
Phase 3
41 of 93
9 open now
Primary completion
2026-10
later than 10 of 38 live
Registered
70th of 93
by date

Among the 93 studies in Hemophilia A with a site in China, this one is the 10th largest by enrollment of the 80 interventional ones that give a count, is one of 10 that started in 2024, is one of 41 in phase 3, reaches primary completion later than 10 of the 38 other live ones, and was the 70th registered.

Hemophilia A

844 studies on the registry are indexed under Hemophilia A; 136 are open to participants now.

Browse Hemophilia A studies →

Open to participants now

28 of the 93 studies in Hemophilia A with a site in China are open now. Recruiting first, the newest first:

23 more — sign in →

All 28 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 87 Hemophilia A studies recruiting now, 51 (59%) set no upper age limit and 31 (36%) stop at 75 or younger; 55 take children under 18; 10 take healthy volunteers.

This study: 12 Years to 70 Years · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 93 studies in Hemophilia A with a site in China, or all of them as a file.
02

Study summary

The purpose of this study is to show that KN057 can prevent bleeds in patients with haemophilia A or B without inhibitors and is safe to use. Participants receiving on-demand treatment prior to screening will be randomly assigned to Experimental group or Control group at a ratio of 2:1 in Part A. Participants receiving prophylaxis prior to screening will be nonrandomly assigned to Prophylaxis group in Part B. Participants in Experimental group will receive KN057 prophylaxis for 52 weeks upon enrollment. Participants in Control group will first receive on-demand treatment for 26 weeks, then switch to KN057 prophylaxis for 26 weeks. Participants in Prophylaxis group will first receive prophylaxis with coagulation factor for 26 weeks, then switch to KN057 prophylaxis for 26 weeks.

03

Conditions studied

  • Hemophilia A Without Inhibitor
  • Hemophilia B Without Inhibitor
04

Who can participate

Ages eligible
12 Years to 70 Years
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male, 12 to 70 years old at the time of signing (including the cut-off value), body weight ≥30 kg and \<28 kg/m\^2 at screening;
  2. Severe and moderately severe hemophilia A or hemophilia B (FVIII or FIX activity level ≤2%);
  3. FVIII or FIX inhibitor test is negative (\<0.6 BU/ml) or lower than the lower limit of laboratory normal values during the screening period;
  4. There is no history of FVIII or FIX inhibitors in the past; or there has been an inhibitor, but it has been at least 5 years since successful immune tolerance induction therapy (ITI), and the inhibitor has not reappeared (a positive inhibitor was detected after successful ITI);
  5. Use coagulation factor replacement therapy for no less than 100 exposure days before screening;
  6. Have not used Anti-TFPI drugs before;
  7. Be able and agree to elute the original hemophilia drugs.

Participants who are enrolled into Part A must also meet the following criteria:

  1. ≥6 treated bleeding episodes within 26 weeks before screening;
  2. Receiving on-demand treatment, non-standard prophylaxis, or standard prophylaxis no more than 12 weeks before screening;

Participants who are enrolled into Part B must also meet the following criteria:

Being on standard prophylaxis and maintaining it for more than 12 weeks (standard prophylaxis is defined as at least 80% compliance with a predetermined prophylaxis regimen).

Exclusion criteria

Exclusion Criteria:

  1. Have serious or poorly controlled chronic diseases or obvious systemic diseases;
  2. Have a history of thromboembolic disease, or currently have symptoms or signs related to thromboembolic disease or being treated with thrombolytic/antithrombotic therapy;
  3. Have high-risk factors for thrombosis: such as a history of coronary atherosclerotic disease, ischemic disease of important organs, vascular occlusive disease, diseases with a high risk of thrombosis, or indwelling central venous catheter;
  4. The presence of other inherited or acquired bleeding disorders other than hemophilia A and hemophilia B;
  5. Known or suspected to any constituent of the trial product or related products;
  6. Have undergone major surgery (as determined by the investigator) within 3 months before screening, or have elective surgery planned during the study;
  7. Used Emicizumab treatment within 6 months before screening;
  8. Have received any gene therapy for hemophilia in the past;
  9. Other factors that the investigator deems inappropriate for participating in this trial, such as the presence of concomitant diseases, treatment or examination abnormalities that affect the subject's safety during the trial or affect the interpretation of trial results.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
125 participants (actual)

Study arms

  • Experimental
    Part A:Experimental group

    Successfully screened participants in Part A will be randomly assigned to Experimental group versus Control group at a ratio of 2:1. Participants in Experimental group will receive KN057 prophylaxis through the main trial (26 weeks) and extension period (26 weeks) for total of approximately 1 year.

    Drug: KN057

  • Experimental
    Part A:Control group

    Successfully screened participants in Part A will be randomly assigned to Experimental group versus Control group at a ratio of 2:1. Participants in Control group will continue on-demand treatment with coagulation factor through the main trial for 26 weeks, in the extension period they will switch to prophylaxis treatment and receive KN057 for 26 weeks.

    Drug: KN057

  • Experimental
    Part B:Prophylaxis group

    Successfully screened participants in Part B will be nonrandomly assigned to Prophylaxis group. Participants in Prophylaxis group will continue prophylaxis with coagulation factor for the first 26 weeks (the factor period), then they will switch to prophylaxis with KN057 for the last 26 weeks (the KN057 period).

    Drug: KN057

Interventions

  • DrugKN057

    KN057 will be administered subcutaneously once a week.

06

What researchers measure

Primary outcomes

  1. Part A: Annualized bleeding rate (ABR) calculated based on treated spontaneous and traumatic bleeding episodes in Experimental group and Control group.

    Treated bleeding refers to the use of coagulation factors for hemostatic treatment of the bleeding.

    Time frame: From Week 1 to Week 26, through the main trial.

  2. Part B: ABR calculated based on treated spontaneous and traumatic bleeding episodes in Prophylaxis group.

    Treated bleeding refers to the use of coagulation factors for hemostatic treatment of the bleeding.

    Time frame: From Week 1 to Week 26, through the factor period. From Week 27 to Week 52, through the KN057 period.

Secondary outcomes

  1. ABR calculated based on bleeding episodes, treated spontaneous and traumatic bleeding episodes, treated spontaneous bleeding episodes, treated joint bleeding episodes, and treated target joint bleeding respectively in Experimental group.

    Bleeding episodes includes spontaneous and/or traumatic bleeding episodes, excluding surgery/procedure-related bleeding episodes. Treated bleeding refers to the use of coagulation factors for hemostatic treatment of the bleeding. Target joint are those with spontaneous bleeding ≥3 times in the 6 months prior to screening.

    Time frame: From Week 1 to Week 52, through the main trial and extension period.

  2. ABR calculated based on bleeding episodes, treated spontaneous bleeding episodes, treated joint bleeding episodes, and treated target joint bleeding respectively in Experimental group, Control group and Prophylaxis group.

    Bleeding episodes includes spontaneous and/or traumatic bleeding episodes, excluding surgery/procedure-related bleeding episodes. Treated bleeding refers to the use of coagulation factors for hemostatic treatment of the bleeding. Target joint are those with spontaneous bleeding ≥3 times in the 6 months prior to screening.

    Time frame: From Week 1 to Week 26. From Week 27 to Week 52.

  3. Proportion of participants with untreated bleeding episodes in Experimental group, Control group and Prophylaxis group.

    Treated bleeding refers to the use of coagulation factors for hemostatic treatment of the bleeding.

    Time frame: From Week 1 to Week 26. From Week 27 to Week 52.

  4. The annual usage of on-demand treatment drugs (adjusted by body weight) in Experimental group and Control group.

    Time frame: From Week 1 to Week 26. From Week 27 to Week 52.

  5. Change from baseline in Hemophilia Joint Health Score (HJHS) scores in Experimental group, Control group and Prophylaxis group.

    Hemophilia Joint Health Scores (HJHS) is a validated 11-item scoring tool developed for the assessment of joint health in participants with hemophilia. It comprised an evaluation of the elbows, knee and ankle joints: swelling (0 to 3), duration of swelling (0 and 1), muscle atrophy (0 to 2), crepitus on motion (0 to 2), flexion loss (0 to 3), extension loss (0 to 3), joint pain (0 to 2) and strength (0 to 4), in each item 0 = none and higher score = severe damage and global gait (walking, stairs, running, hopping on 1 leg) scored on scale ranged from 0 to 4, where 0 = all skills in normal limit and 4 = no skills within normal limits). Total HJHS score = sum of joint totals (0 to 120) + general gait (1 to 4) and ranged from 0 (no joint damage) to 124 (severe joint damage), where higher score indicated severe joint damage.

    Time frame: From Week 1 to Week 26.

  6. Change in HJHS scores from baseline in Experimental group, from the 26th week in Control group, from baseline and the 26th week in Prophylaxis group.

    Hemophilia Joint Health Scores (HJHS) is a validated 11-item scoring tool developed for the assessment of joint health in participants with hemophilia. It comprised an evaluation of the elbows, knee and ankle joints: swelling (0 to 3), duration of swelling (0 and 1), muscle atrophy (0 to 2), crepitus on motion (0 to 2), flexion loss (0 to 3), extension loss (0 to 3), joint pain (0 to 2) and strength (0 to 4), in each item 0 = none and higher score = severe damage and global gait (walking, stairs, running, hopping on 1 leg) scored on scale ranged from 0 to 4, where 0 = all skills in normal limit and 4 = no skills within normal limits). Total HJHS score = sum of joint totals (0 to 120) + general gait (1 to 4) and ranged from 0 (no joint damage) to 124 (severe joint damage), where higher score indicated severe joint damage.

    Time frame: From Week 1 to Week 52.

  7. Change from baseline in EuroQol 5 Dimensions 5 Level (EQ-5D-5L) in Experimental group, Control group and Prophylaxis group.

    The EQ-5D-5L questionnaire is made up for 2 components, health state description and evaluation. In description part, health status is measured in terms of 5 dimensions (5D): mobility, self-care, usual activities, pain/discomfort, and anxiety/depression; every dimension contains 5 levels (5L): no difficulty, a little difficulty, moderate difficulty, severe difficulty, very severe difficulty/inability to perform. In evaluation part, the respondents evaluate their overall health status using the visual analogue scale (EQ-VAS) ranging from 0 (worst imaginable health) to 100 (best imaginable health).

    Time frame: From Week 1 to Week 26.

  8. Change in EQ-5D-5L from baseline in Experimental group, from the 26th week in Control group, from baseline and the 26th week in Prophylaxis group.

    The EQ-5D-5L questionnaire is made up for 2 components, health state description and evaluation. In description part, health status is measured in terms of 5 dimensions (5D): mobility, self-care, usual activities, pain/discomfort, and anxiety/depression; every dimension contains 5 levels (5L): no difficulty, a little difficulty, moderate difficulty, severe difficulty, very severe difficulty/inability to perform. In evaluation part, the respondents evaluate their overall health status using the visual analogue scale (EQ-VAS) ranging from 0 (worst imaginable health) to 100 (best imaginable health).

    Time frame: From Week 1 to Week 52.

  9. Incidence of TEAE, TEAE related to the experimental drug and SAE.

    TEAE refers to 'treatment emergent adverse event'. SAE refers to 'serious adverse event'.

    Time frame: From the signing of informed consent to 4 weeks after the last dose of KN057 (the end of the trial), approximately 59 weeks in total.

  10. Incidence of thromboembolic events, TMA and DIC.

    TMA refers to 'thrombotic microangiopathy'. DIC refers to 'disseminated intravascular coagulation'.

    Time frame: From the signing of informed consent to 4 weeks after the last dose of KN057 (the end of the trial), approximately 59 weeks in total.

  11. Incidence of hypersensitivity type reactions.

    Time frame: From the signing of informed consent to 4 weeks after the last dose of KN057 (the end of the trial), approximately 59 weeks in total.

  12. Incidence of injection site reactions.

    Time frame: From the signing of informed consent to 4 weeks after the last dose of KN057 (the end of the trial), approximately 59 weeks in total.

  13. Incidence of clinically significant laboratory value abnormalities.

    Time frame: From the signing of informed consent to 4 weeks after the last dose of KN057 (the end of the trial), approximately 59 weeks in total.

  14. Number of participants with clinically significant changes from baseline in physical exam.

    Time frame: From the signing of informed consent to 4 weeks after the last dose of KN057 (the end of the trial), approximately 59 weeks in total.

  15. Number of participants with clinically significant changes from baseline in electrocardiograms.

    Time frame: From the signing of informed consent to 4 weeks after the last dose of KN057 (the end of the trial), approximately 59 weeks in total.

  16. Number of participants with clinically significant changes from baseline in vital signs.

    Time frame: From the signing of informed consent to 4 weeks after the last dose of KN057 (the end of the trial), approximately 59 weeks in total.

  17. KN057 plasma concentration.

    pharmacokinetics

    Time frame: From start of KN057 treatment (Week 1 for Experimental group, Week 26 for Control group and Prophylaxis group) to 4 weeks after the last dose of KN057, approximately 56 weeks for Experimental group and 30 weeks for Control group and Prophylaxis group.

  18. Levels of Total TFPI.

    pharmacodynamics

    Time frame: From start of KN057 treatment (Week 1 for Experimental group, Week 26 for Control group and Prophylaxis group) to 4 weeks after the last dose of KN057, approximately 56 weeks for Experimental group and 30 weeks for Control group and Prophylaxis group.

  19. Levels of Free TFPI.

    pharmacodynamics

    Time frame: From start of KN057 treatment (Week 1 for Experimental group, Week 26 for Control group and Prophylaxis group) to 4 weeks after the last dose of KN057, approximately 56 weeks for Experimental group and 30 weeks for Control group and Prophylaxis group.

  20. Levels of prothrombin fragment 1+2 (PF1+2).

    pharmacodynamics

    Time frame: From start of KN057 treatment (Week 1 for Experimental group, Week 26 for Control group and Prophylaxis group) to 4 weeks after the last dose of KN057, approximately 56 weeks for Experimental group and 30 weeks for Control group and Prophylaxis group.

  21. Incidence of anti-KN057 antibody (ADA) and neutralizing antibody (Nab).

    immunogenicity

    Time frame: From start of KN057 treatment (Week 1 for Experimental group, Week 26 for Control group and Prophylaxis group) to 4 weeks after the last dose of KN057, approximately 56 weeks for Experimental group and 30 weeks for Control group and Prophylaxis group.

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2024 (actual). Primary completion is estimated for Oct 2026, 30 months after the start.

Of 89 industry-sponsored phase 3 interventional studies under Hemophilia A, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 56. This study's planned 30 months is close to that.

Counting every sponsor, half of 91 studies reached it within 33 months; a quarter within 20 and three quarters within 56.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 30, 2023
First posted
Aug 23, 2024
StartActual
Apr 1, 2024
Primary completionEst.
Oct 15, 2026
CompletionEst.
Dec 15, 2026
Last update
Sep 17, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 17, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06569108
Lead sponsor
Suzhou Alphamab Co., Ltd.
Responsible party
Sponsor
First posted
Aug 23, 2024
Start date
Apr 1, 2024
Primary completion
Oct 15, 2026 (estimated)
Completion
Dec 15, 2026 (estimated)
Last update
Sep 17, 2025

Study contacts

Renchi Yang, Doctor
principal investigator · Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences
Jing Sun, Doctor
principal investigator · Nanfang Hospital, Southern Medical University
Hu Zhou, Doctor
principal investigator · Henan Cancer Hospital
Changcheng Zheng, Doctor
principal investigator · The First Affiliated Hospital of China University of Science and Technology (Anhui Provincial)
Xielan Zhao, Doctor
principal investigator · Xiangya Hospital of Central South University
Lili Chen, Doctor
principal investigator · Tai Zhou First People's Hospital
Chenghao Jin, Doctor
principal investigator · Jiangxi Provincial People's Hopital
Yanping Song, Doctor
principal investigator · Xi'an Central Hospital
Yaming Xi, Doctor
principal investigator · LanZhou University
Zeping Zhou, Doctor
principal investigator · The Second Affiliated Hospital of Kunming Medical University
Runhui Wu, Doctor
principal investigator · Beijing Children's Hospital
Jingyu Yan, Doctor
principal investigator · North China University of Science and Technology
Sujun Gao, Doctor
principal investigator · Bethune First Hospital of Jilin University
Wei Yang, Doctor
principal investigator · Shengjing Hospital of China University
Rong Zhou, Doctor
principal investigator · The Third People's Hospital of Chengdu
Ziqiang Yu, Doctor
principal investigator · The First Affiliated Hospital of Soochow University
Yun Chen, Doctor
principal investigator · Qianfoshan Hospital
Pingchong Lei, Doctor
principal investigator · Henan Provincial People's Hospital
Yinsuo Zheng, Doctor
principal investigator · Bao Ji Central Hospital
Peng Cheng, Doctor
principal investigator · First Affiliated Hospital of Guangxi Medical University
Jianwen Xiao, Doctor
principal investigator · Children's Hospital of Chongqing Medical University
Ruibin Huang, Doctor
principal investigator · The First Affiliated Hospital of Nanchang University
Hailiang Li, Doctor
principal investigator · The first affiliated hospital of jiangxi medical college
Shu Chen, Doctor
principal investigator · The Second Affiliated Hospital of Chongqing Medical University
Xiong Zhang, Doctor
principal investigator · Maoming City People's Hospital
Jingyu Zhang, Doctor
principal investigator · The Second Hospital of Hebei Medical Hospital
Baolai Hua, Doctor
principal investigator · Beijing Shijitan Hospital, Capital Medical University
Yanming Zhang, Doctor
principal investigator · Huai'an Second People'Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Sep 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: KN057

Start the discussion